1Ashish KJ,Gilad JK,Eve R, et al. Identifying hospital admissions due to adverse drug events using a computer-based momtor.Pharmacoepidemiology and Drug Safety , 2001.10:113-119.
2Peachey J, From Pharmacovigilance to Pharmacoperformance. Drug Safety, 2002,259(6) :399-405.
3Arlett PR, Harrison P. Compliance in European pharmacovilance: a regulatory view. Pharmacoepidemiology and Drug Safety, 2001,10:301-302.
4Grootheest ACV, Puijenbroek EPV, Jong LTD. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2002, 11 :205-210.
5Lumley CE, Walker SR,Hall GC, et al. The under-reporting of adverr, e reactions in general practice, Pharm Med,1986,1 : 205-212.
6Anon. Yellow card reporting by doctors. Current Problem in Pharmacovigilance . 1997,23: 6.
7Olsson S. editor. National pharmacovigilance systems:Country profiles and overview. Uppsala: The Uppsala Monitoring Centre, 1999.
8George CF, Rabin KH. Improving patient information and education on medicines. Report from the foundation's Committee on Patient Information. GENEVA, Swi~rland: International Medical Benefit/Risk Foundation-RAD-AR,1993.14-15.
9Smith DL. Staggering cost of home medicine errors: the over-looked cost in prescription drug coverage. Taking control of your medicines. Mclean, (VA):Consumer Health Corporation, 2001.
